Literature DB >> 21171883

Subarachnoid basal neurocysticercosis: a focus on the most severe form of the disease.

Agnès Fleury1, Roger Carrillo-Mezo, Ana Flisser, Edda Sciutto, Teresa Corona.   

Abstract

Neurocysticercosis is an endemic disease in Latin America, Asia and Africa with growing occurrence in industrialized countries due to the increase in migration from low- and middle-income to high-income countries. The most severe clinical presentation is when the parasite is located in the subarachnoid space at the base of the brain (NCSAB). Aside from its clinical presentation, the severity of this form of the disease is due to the difficulties in diagnosis and treatment. Although NCSAB frequency is lower than that reported for the parenchymal location of the parasite, its clinical relevance must be emphasized. We provide a critical review of the central epidemiological, clinical, diagnostic and therapeutic features of this particular form of the disease, which is still associated with unacceptably high rates of morbidity and mortality.

Entities:  

Mesh:

Year:  2011        PMID: 21171883     DOI: 10.1586/eri.10.150

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  45 in total

1.  Neurocysticercosis.

Authors:  Oscar H Del Brutto
Journal:  Neurohospitalist       Date:  2014-10

2.  A Novel, Highly Sensitive Quantitative Polymerase Chain Reaction Assay for the Diagnosis of Subarachnoid and Ventricular Neurocysticercosis and for Assessing Responses to Treatment.

Authors:  Elise M O'Connell; Sarah Harrison; Eric Dahlstrom; Theodore Nash; Thomas B Nutman
Journal:  Clin Infect Dis       Date:  2020-04-15       Impact factor: 9.079

3.  Neurocysticercosis: Five new things.

Authors:  Arturo Carpio; Agnès Fleury; W Allen Hauser
Journal:  Neurol Clin Pract       Date:  2013-04

Review 4.  Clinical symptoms, diagnosis, and treatment of neurocysticercosis.

Authors:  Hector H Garcia; Theodore E Nash; Oscar H Del Brutto
Journal:  Lancet Neurol       Date:  2014-11-10       Impact factor: 44.182

Review 5.  Current status and future perspectives on the medical treatment of neurocysticercosis.

Authors:  Isidro Gonzales; Hector H Garcia
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

6.  Neurocysticercosis: the effectiveness of the cysticidal treatment could be influenced by the host immunity.

Authors:  Graciela Cárdenas; Gladis Fragoso; Marcos Rosetti; Laura Uribe-Figueroa; Claudia Rangel-Escareño; Brenda Saenz; Marisela Hernández; Edda Sciutto; Agnes Fleury
Journal:  Med Microbiol Immunol       Date:  2014-06-24       Impact factor: 3.402

7.  The HP10 Taenia monoclonal antibody-based ELISA detects a similar protein in the vesicular fluid of Taenia hydatigena.

Authors:  Maria M Cortez; Glenda C Rojas; R Michael E Parkhouse
Journal:  Trop Anim Health Prod       Date:  2017-11-16       Impact factor: 1.559

8.  Calcified Neurocysticercosis and Headache in an Endemic Village: A Case-Control Study Nested to a Population-Based Cohort.

Authors:  Oscar H Del Brutto; Ana M Robles; Robertino M Mera; Aldo F Costa; Elizabeth Darsan; Lucía Milla; Jessica Montes; Julio Lama; Victor J Del Brutto; Mauricio Zambrano; Mark J Sedler
Journal:  Am J Trop Med Hyg       Date:  2018-06-21       Impact factor: 2.345

9.  Microsurgical Treatment of Epilepsy with Parenchymal Neurocysticercosis.

Authors:  Yu-Tang Tan; Suo-Jun Zhang; Kai Shu; Ting Lei; Hong-Quan Niu
Journal:  Curr Med Sci       Date:  2019-12-16

Review 10.  Immunology of Taenia solium taeniasis and human cysticercosis.

Authors:  H H Garcia; S Rodriguez; J S Friedland
Journal:  Parasite Immunol       Date:  2014-08       Impact factor: 2.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.